Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.60 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.59 |
| ▸ | TYMP | P19971 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8332109 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL918582 | 0.92 | TYMP (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL12513082 | 0.92 | TYMP (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL918583 | 0.92 | TYMP (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL1317089 | 0.92 | TYMP (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL12434636 | 0.92 | TYMP (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL26502752 | 0.92 | TYMP (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL3316264 | 0.91 | P2RY14 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5671913 | 0.90 | P2RY6 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7922849 | 0.90 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053443-A | Application of 5' -O-trityl uridine and derivatives thereof in preparation of medicines for treating cerebral infarction | 中国中医科学院中医药健康产业研究所 | 2025-05-30 | — | — | CN | claimed |
| EP-0682670-B1 | DEOXYGENATION OF CIS VICINAL DIOLS | RAYLO CHEMICALS INC (CA) | 1998-05-06 | — | — | EP | claimed |
| US-5410033-A | Deoxygenation of cis vicinal diols to make didehydro dideoxy nucleosidies and synthetic intermediates | TEROCHEM LABORATORIES LIMITED (CA) | 1995-04-25 | — | — | US | claimed |
| CN-120053443-A | Application of 5' -O-trityl uridine and derivatives thereof in preparation of medicines for treating cerebral infarction | 中国中医科学院中医药健康产业研究所 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053443-A | Application of 5' -O-trityl uridine and derivatives thereof in preparation of medicines for treating cerebral infarction | 中国中医科学院中医药健康产业研究所 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053443-A | Application of 5' -O-trityl uridine and derivatives thereof in preparation of medicines for treating cerebral infarction | 中国中医科学院中医药健康产业研究所 | 2025-05-30 | — | — | CN | disclosed |
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1644479-A4 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1644479-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | Grinstaff, Mark, W. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007810-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-0682670-B1 | DEOXYGENATION OF CIS VICINAL DIOLS | RAYLO CHEMICALS INC (CA) | 1998-05-06 | — | — | EP | disclosed |
| US-5410033-A | Deoxygenation of cis vicinal diols to make didehydro dideoxy nucleosidies and synthetic intermediates | TEROCHEM LABORATORIES LIMITED (CA) | 1995-04-25 | — | — | US | disclosed |
| US-5212294-A | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-05-18 | — | — | US | disclosed |
| US-5130421-A | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | BRISTOL-MYERS COMPANY (US) | 1992-07-14 | — | — | US | disclosed |
| US-4904770-A | Production of 2',3'-dideoxy-2',3'-didehydronucleosides | BRISTOL-MYERS COMPANY (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0334368-A2 | Production of 2',3'-dideoxy-2',3'-Didehydronucleosides | Bristol-Myers Squibb Company (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0316017-A2 | 2',3'-Dideoxy-2'-fluoronucleosides | Bristol-Myers Squibb Company (US) | 1989-05-17 | — | — | EP | disclosed |
| EP-0082668-A1 | 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections | BEECHAM GROUP PLC (GB) | 1983-06-29 | — | — | EP | disclosed |
| EP-0061283-A1 | Antiviral agents, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | ANXA6, STING1, POLRMT | SLC28A1 1592/4885SLC28A2 1890/4885SLC29A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.